BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.
PDS Biotechnology Corp (PDSB) progresses in clinical trials and patent protection, but faces financial hurdles and competitive pressures.
12d
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients
Dr. Kirk Shepard (Chief Medical Officer) detailed a pivotal change to the Phase III VERSATILE-003 study design: “we adopted an amendment to our VERSATILE-003 trial, revising the design to incorporate ...
On average, penetrative sex lasts about 5.4 minutes. Many people think sex is over when the male ejaculates, but sex can continue in other ways. If you’re wondering how long sex should last, you might ...
In a major shift for the global pharmaceutical industry, Mounjaro - the diabetes and obesity treatment developed by Eli Lily - has officially overtaken Keytruda to become the world’s top-selling ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s best-selling medication. Mounjaro generated $8.7 billion for Lilly in the first ...
Eli Lilly’s diabetes drug Mounjaro has become the world’s top-selling medication, surpassing Merck’s cancer therapy Keytruda. Lilly’s performance compounded when Mounjaro and weight-loss drug Zepbound ...
Eli Lilly's diabetes drug Mounjaro brought in nearly $9 billion in the first quarter of 2026, surpassing the nearly $8 billion in sales for Merck's Keytruda, a cancer therapy. Bloomberg: Lilly’s ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s best-selling medication. Mounjaro generated $8.7 billion for Lilly in the first ...
Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results